Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » New Drug Connects Dots That Cause Clots in COVID-19 Patients
Clinical Breakthroughs

New Drug Connects Dots That Cause Clots in COVID-19 Patients

By Marla PaulDec 4, 2020
Share
Facebook Twitter Email

Listen to an episode of the Breakthroughs Podcast on this research:

Approach inspired by a gene mutation in Indiana Swiss Amish that reduces clotting

Douglas Vaughan, MD, chair and Irving S. Cutter Professor of Medicine, is the lead investigator on the trial.

A gene mutation discovered in a small Amish community in Indiana has inspired the use of a new experimental drug for COVID-19 that reduces blood clotting, which is a primary driver of morbidity and organ damage in the disease.

The first clinical trial of the drug in COVID-19 patients has just been launched at Northwestern Medicine.

“This provides a whole new approach of thinking about how to reduce the severity of illness in patients with COVID — largely through the potential impact on clotting,” said lead investigator Douglas Vaughan, MD, chair and Irving S. Cutter Professor of Medicine . “Until now, no one has pulled together a drug target that captures the constellation of factors that put people at high risk for bad outcomes.”

The new experimental drug reduces the activity of a protein called PAI-1 in the blood. High PAI-1 levels alone are enough to cause clotting in arteries that supply blood to the heart and the lungs in experimental models. Lower levels of PAI-1 reduce clotting, a primary driver of damage to the lungs, heart, kidneys and brain, as well as overall mortality in patients hospitalized with COVID-19.

The leading clinical risk factors for poor outcomes in patients with COVID-19 — age, obesity, diabetes, hypertension — are all associated with increased blood levels of PAI-1 and together have an additive effect in increasing PAI-1. In fact, one of the most powerful clinical predictors of severity of illness in COVID-19 is obesity, which is also the most important determinant of blood PAI-1 levels in adults.”

Vaughan and colleagues at Northwestern have measured blood PAI-1 levels in over 30 patients hospitalized with COVID.

“The PAI-1 levels in the COVID-19 patients tested so far are 10 times higher than normal,” Vaughan said. “Nearly 30% of these patients have levels higher than we have ever seen in adults, far beyond levels measured in thousands of non-COVID patients over the last 25 years. This alone could drive the clotting problem and needs to be addressed.”

The drug, TM5614, is in tablet form and will be tested in 80 high-risk patients hospitalized with COVID in a phase two clinical trial.

In 2017, Vaughan and colleagues published a study reporting a community of Swiss Amish in Indiana had a mutation in the gene that codes for the protein PAI-1, so they produced less of it. This reduction in PAI-1 appears to protect against biological aging in a variety of ways.

“We now know that age is the most important risk factor in patients with COVID-19,” Vaughan said. “Knowing the relationship of PAI-1 to aging itself is another emerging connection as to how PAI-1 might impact on the severity of illness.”

The drug is now being developed to potentially prevent a variety of aging-related diseases based on research findings from the Vaughan laboratory. Vaughan is the leading physician-scientist in the world in the study of PAI-1, and his research has almost exclusively focused on PAI-1 for more than 30 years. He showed years ago that excess PAI-1 alone will make animals have heart attacks by causing clotting in the coronary arteries.

It turns out PAI-1 is a unique factor that impairs the function of all three internal systems that protect us from clotting.

The drug TM5614 was originally developed in Japan based on the idea that inhibition of PAI-1 might be useful in slowing the progression of kidney disease in patients with diabetes. Based on work done in Vaughan’s laboratory at Northwestern and in others around the world, evidence shows that PAI-1 contributes to a number of different metabolic, cardiovascular, fibrotic and aging-related disorders.

Cardiology COVID-19 Press Release Research
Share. Facebook Twitter Email

Related Posts

Scientists Discover Novel Cellular Mechanisms Behind Transcription Elongation

Aug 10, 2022

‘Inside Out’ Signaling Promotes Tumor Growth

Aug 5, 2022

New Insights in Retinal Neurons

Aug 4, 2022

Comments are closed.

Latest News

Scientists Discover Novel Cellular Mechanisms Behind Transcription Elongation

Aug 10, 2022

First-Year Medical Students Celebrate Founders’ Day 2022

Aug 9, 2022

‘Inside Out’ Signaling Promotes Tumor Growth

Aug 5, 2022

New Insights in Retinal Neurons

Aug 4, 2022

Medical Student Wins Presidential Fellowship

Aug 3, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
220805_SERIO_MANDELL_FEINBERG_White_Coat_1676
220805_SERIO_MANDELL_FEINBERG_White_Coat_1206
220805_SERIO_MANDELL_FEINBERG_White_Coat_1144 (1)
220805_SERIO_MANDELL_FEINBERG_White_Coat_1133
220805_SERIO_MANDELL_FEINBERG_White_Coat_1057
220805_SERIO_MANDELL_FEINBERG_White_Coat_1424
220805_SERIO_MANDELL_FEINBERG_White_Coat_1472
220805_SERIO_MANDELL_FEINBERG_White_Coat_1573
220805_SERIO_MANDELL_FEINBERG_White_Coat_1671
220805_SERIO_MANDELL_FEINBERG_White_Coat_1793
220805_SERIO_MANDELL_FEINBERG_White_Coat_0885
220805_SERIO_MANDELL_FEINBERG_White_Coat_1144

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.